Evidence map›Paper›PMID 33127499›Full record

Observational studyInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021

COVID-19 in people living with HIV: A multicenter case-series study.

Alfonso Cabello, Belén Zamarro, Sara Nistal, Virginia Victor, Jana Hernández, Laura Prieto-Pérez, Irene Carrillo, Beatriz Álvarez, Ricardo Fernández-Roblas, Marta Hernández-Segurado and 7 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Profile of SARS-CoV-2/HIV-1 coinfection in patients from the extreme south of Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alfonso CabelloDivision of Infectious Diseases, Fundación Jiménez Díaz University Hospital, Research Health Institute, Autónoma de Madrid University (IIS-FJD, UAM), Spain. Electronic address: acabello@fjd.es.
Belén ZamarroDivision of Infectious Diseases, Fundación Jiménez Díaz University Hospital, Research Health Institute, Autónoma de Madrid University (IIS-FJD, UAM), Spain.
Sara NistalInfectious Diseases Unit, Rey Juan Carlos University Hospital, IIS-FJD, Spain.
Virginia VictorInfectious Diseases Unit, Infanta Elena University Hospital, IIS-FJD, Spain.
Jana HernándezInfectious Diseases Unit, Villalba General Hospital, IIS-FJD, Spain.
Laura Prieto-PérezDivision of Infectious Diseases, Fundación Jiménez Díaz University Hospital, Research Health Institute, Autónoma de Madrid University (IIS-FJD, UAM), Spain.
Irene CarrilloDivision of Infectious Diseases, Fundación Jiménez Díaz University Hospital, Research Health Institute, Autónoma de Madrid University (IIS-FJD, UAM), Spain.
Beatriz ÁlvarezDivision of Infectious Diseases, Fundación Jiménez Díaz University Hospital, Research Health Institute, Autónoma de Madrid University (IIS-FJD, UAM), Spain.
Ricardo Fernández-RoblasDepartment of Clinical Microbiology, Fundación Jiménez Díaz University Hospital, IIS-FJD, UAM, Spain.
Marta Hernández-SeguradoDepartment of Pharmacy, Fundación Jiménez Díaz University Hospital, IIS-FJD, UAM, Spain.
Javier BecaresDepartment of Pharmacy, Fundación Jiménez Díaz University Hospital, IIS-FJD, UAM, Spain.
José Miguel BenitoHIV and Viral Hepatitis Research Laboratory, IIS-FJD, UAM, Spain.
Norma RallónHIV and Viral Hepatitis Research Laboratory, IIS-FJD, UAM, Spain.
Raquel TéllezDepartment of Immunology, Fundación Jiménez Díaz University Hospital, IIS-FJD, UAM, Spain.
Ángel Luis CastañoDepartment of Immunology, Fundación Jiménez Díaz University Hospital, IIS-FJD, UAM, Spain.
Antonio HerreroData Analytics Director, Fundación Jiménez Díaz University Hospital, IIS-FJD, Spain.
Miguel GórgolasDivision of Infectious Diseases, Fundación Jiménez Díaz University Hospital, Research Health Institute, Autónoma de Madrid University (IIS-FJD, UAM), Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesInformation on how COVID-19 affects people living with HIV (PLHIV) remains scarce.

methodsAn observational study was conducted in four public hospitals in Madrid. All HIV patients with confirmed or suspected COVID-19 were included and compared with COVID-19 patients without HIV infection.

resultsSixty-three patients with HIV infection and confirmed or suspected COVID-19 were analyzed. The median age was 46 years (IQR: 37-56 years), and 88.9% were men. The median duration of HIV infection was 10.8 years (IQR: 6.5-16.8 years), and 96.8% were on antiretroviral therapy. 84.1% had previous comorbidities. The most common symptoms were fever (66.1%), cough (66.1%) and dyspnea (46.8%). Pneumonia was found in 47.5%, 28.6% of patients had severe disease, and 32.3% were admitted to hospital. The ICU admission rate and the mortality rate were both 3.17%. A significant association was observed between age, arterial hypertension, overweight, and diabetes mellitus and the severity of COVID-19. No association was observed between HIV-related factors and the severity of COVID-19. The rate of COVID-19 in HIV-patients was 1.68%. Similar hospitalization (31.74% vs 32.57%) and ICU admission (3.17% vs 2%) rates were observed with non-HIV infected patients. A lower mortality rate during hospitalization (10% vs 21.37%) and a lower global mortality rate (3.17% vs 6.96%) were also observed.

conclusionsEstablished poor prognostic factors for COVID-19 patients, such as age and comorbidities, remain the main determinants for PLHIV. Neither the HIV severity nor the type of ARV treatment seem to influence the outcome of COVID-19. Large prospective cohorts are needed in order to establish the differences between HIV-positive and HIV-negative patients.

Indexed as

AdultComorbidityCOVID-19FemaleHIV InfectionsHospitalizationHumansIntensive Care UnitsMaleMiddle AgedProspective StudiesCOVID-19HIVSARS-CoV-2

Identifiers

PMID33127499
PMCPMC7590815

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.